[go: up one dir, main page]

WO2009079939A1 - A method for preparing zopiclone - Google Patents

A method for preparing zopiclone Download PDF

Info

Publication number
WO2009079939A1
WO2009079939A1 PCT/CN2008/072007 CN2008072007W WO2009079939A1 WO 2009079939 A1 WO2009079939 A1 WO 2009079939A1 CN 2008072007 W CN2008072007 W CN 2008072007W WO 2009079939 A1 WO2009079939 A1 WO 2009079939A1
Authority
WO
WIPO (PCT)
Prior art keywords
zopiclone
pyridine
oxo
reaction
gas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2008/072007
Other languages
French (fr)
Chinese (zh)
Inventor
Zhongnan Chen
Puren Wei
Baoyong Li
Baogang Ren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qilu Tianhe Pharmaceutical Co Ltd
Original Assignee
Qilu Tianhe Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qilu Tianhe Pharmaceutical Co Ltd filed Critical Qilu Tianhe Pharmaceutical Co Ltd
Publication of WO2009079939A1 publication Critical patent/WO2009079939A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Definitions

  • the invention relates to a method for synthesizing a compound, in particular to a method for preparing zopiclone.
  • the retention effect is relatively small, and the phenomenon of “sleeping” rarely occurs in the morning, which does not affect the mental activity of the morning. And the sensitivity of the action, and the amount of reversal is small, and the repeated application also reduces accumulation, so it is safer.
  • reaction solution is poured into ice water during crystallization, which makes the pyridine difficult to collect, if the mother liquor (* ingot mixed with water) Liquid> Abandoned, not only increases the cost but also is not conducive to environmental protection.
  • the radiance is out of the bottom, and the requirements of the European Pharmacopoeia are not met.
  • the object of the present invention is to overcome the deficiencies of the prior art and to provide a novel method for synthesizing zopiclone which is characterized by safety and reliability, short reaction time > high reaction yield and good product quality.
  • the hydrazide-4-propenylpiperazine acid salt is used as a raw material, and is obtained by reacting a 4-substituted pyridine as a catalyst under an alkaline condition in an anhydrous organic solvent.
  • the reaction formula is as follows;
  • R is a tertiary amino group, a C! C8 linear or branched alkane, a C? ⁇ C « aryl alkane, a C3 ⁇ C8 cycloalkane, an aromatic group.
  • the anhydrous organic solvent is one or more of gas-married, acetonitrile, tetrachlorofuran, dioxane, acetone, ethyl acetate, '-dimethylformamide, preferably di-methane.
  • the anhydrous organic solvent is 6 to 50 times by weight of 6 (:5 chloro-2-pyridyl) 5 3 ⁇ 4 yl-oxo-oxo, 6 ⁇ di-[3,4- 3 pyridinium;
  • the amount of anhydrous organic solvent is 6-(5-weityl)- ⁇ -trans-yl-7-oxo- ⁇ , 6-dioxazide and [3, 4 b]azine in the amount of 25 ⁇ 35S
  • the alkaline condition is an organic base, and particularly preferably from methylamine, diethylamine, triethylamine, dipropylamine, diisopropylamine, cyclic diamine, cycloethylamine, aniline, methylamine, N, One or a combination of dimethylaniline or pyridine.
  • the amount of organic base added is 1.1.
  • the catalyst 4-substituted pyridine selected from the group consisting of 4-dimethylaminopyrazole, -ylpyridine, 4-P-glycolyl 3 ⁇ 4 pyridine, 4-piperidinyl*pyridine., - (4 methyl-1 Shouting pyridine) 3 ⁇ 4 pyridine or 4 - one of the Marinji clocks,
  • pyridine is added as a co-solvent, and the amount thereof is 6-( ⁇ -gas-2-nyl) 5 hydroxy 7 oxo-5,6-diaminopyrrolo[3,4-azine 1 to 2 times (by weight).
  • the molar ratio of the catalyst to the starting material 6-( ⁇ -Gas-2-pyridyl)-5-yl-7-oxo-5,6-dichloropyrrolo[4b]pyrazine is (0. H ⁇ 0,5): 1.
  • the starting material 6 ⁇ - (5 «-2 P pyridine) 5-hydroxy?
  • the molar ratio of oxo-5,6-.dioxapyrrolo[3,4-b]pyridinium to i-3 ⁇ 4formyl-4-methylpyrazine salt is i: (1-1,7) ),
  • the reaction temperature is from iO to the boiling point of the solvent system.
  • the reaction time is i ⁇ 4, 5 hours. More preferably, the reaction time is preferably 1.5 to 3.5 hours.
  • the following post treatment is carried out - a water layer is added to the reaction system, the water layer is discarded, and the dinitrogen is vacuum concentrated.
  • the preparation method of the zopiclone of the invention adopts an organic solvent which is relatively less toxic and is not flammable, and the reaction is thorough, the purity of the finished product is high, and an ideal yield is obtained.
  • the technical feature of the preparation method of zopiclone of the present invention is also:
  • the catalyst 4-reactive radical "pyridine" of the invention is reacted with the reactant S-(5 chloro-2-pyridyl) 5-hydroxy-?-oxo 6-dioxapyrido[3,4-b]pyrazine
  • the ratio is particularly preferably 0.0i ⁇ 0.5: ⁇ , I have found through experiments that I can't clearly lift the reaction rate when the molar ratio is less than 0.01:1, if it is from 0.5: ⁇ and ⁇ ).01: 1 With 5: 1 There is no significant difference in the improvement of the reaction rate, which increases the amount of catalytic tilt, which increases the production cost.
  • the reaction temperature of the present invention is preferably -10 Torr to the boiling point of the solvent system. If it is lower than ⁇ , the reaction will be delayed, and the reaction will be prolonged, and the labor cost will be increased.
  • the reaction time of the present invention is preferably ⁇ 4 hours. It has been verified by experiments that we found that the reaction time is less than ⁇ hour, which makes the reaction incomplete. The reaction time is higher than 4.5 hours, which not only does not increase the yield of the product, but instead The color of the product is deepened.
  • the preparation method of the zopiclone of the invention has the characteristics of safety and reliability, short reaction time, high reaction yield and good product quality.
  • H high 'pressure liquid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)

Abstract

A method for preparing zopiclone comprises the reaction of raw materials 6-(5-chloro-2-pyridyl)-5-hydroxy-7-oxo-5,6-dihydropyrrolo[3,4-b]pyrazine and 1-chloroformyl-4-methylpiperazine hydrochloride, in an anhydrous organic solvent and alkaline condition in the presence of 4-substituted pyridine as a catalyst. Using organic solvent with low toxicity and not easy to deflagrate, and with a specific catalyst, the method of the present invention is carried completely, obtains the product with high purity and ideal yield.

Description

佐匹克隆的制备方法 技术领域  Preparation method of zopiclone

本发明涉及一种化合物的合成方法, 具体涉及佐匹克隆的制备方法。  The invention relates to a method for synthesizing a compound, in particular to a method for preparing zopiclone.

背景技术 Background technique

佐匹克隆 (Zopickme), 化学名为 (5 S) (5 -氣- 2 - Pft啶基) 7 氧代- 6, 7…二 5Η···吡咯并 [3, 4-b] Pft嗪 5 基 4 甲基喊嗪 I 羧酸盐, 是法国罗鈉普朗克乐安 CRhone-PouIent Rorer) 公司研弒, 属干毗咯环觀类化合物, 作为一种已用于嗨床的新型 非苯二氮卓类镇静催眠药, 用于治疗失眠症, 尤其适用不能耐受次晨残余作用的患者。  Zopick, chemical name (5 S) (5 - gas - 2 - Pft pyridine) 7 oxo - 6, 7... two 5 Η · · · pyrrolo [3, 4-b] Pftazine 5 Base 4 methylpyrazine I carboxylate, is a research institute of Rhone-PouIent Rorer, France. It is a compound of the genus, which is a new type of non-benzene used in trampolines. Diazo sedative hypnotics for the treatment of insomnia, especially for patients who cannot tolerate the residual effects of the morning.

作为第三代非苯二氣类催 K药能选择性地作用于 Β2Ϊ 受体, 产生的遴留效应賴对较 小, 次晨极少产生"宿睡"现象, 不影响次晨的精神活动和动作的机敏度, 而且翻量较小, 重复应用也钹少积聚, 因此较为安全。  As the third-generation non-benzene-based gas-promoting K drug can selectively act on the Β2Ϊ receptor, the retention effect is relatively small, and the phenomenon of “sleeping” rarely occurs in the morning, which does not affect the mental activity of the morning. And the sensitivity of the action, and the amount of reversal is small, and the repeated application also reduces accumulation, so it is safer.

1975年, 美国专利 (US3862149)报遒: 以 M, N -二甲基甲酰胺作为溶剂, 隨化纳 作为催化 6- (δ-氯 -2-吡啶基) -5 -羟基 - 7 -氧代 ~ 5, 6-二氢吡咯并 [3, 4- b吡嗪与 1 氣甲敏棊 - 4 -甲棊哌嗪为原料來制备佐匹克隆。 该方法具有三个问题; L易 燃物品, 大规模生产时安全性难以保障: 2<收率比较低, 粗品收率 76%; 3>精制时采用层 析柱, 不利于大规模生产。  In 1975, US Patent (US 3,862,149) reported: using M, N-dimethylformamide as a solvent, as a catalyst for 6-(δ-chloro-2-pyridyl)-5-hydroxy-7-oxo ~ 5,6-Dihydropyrrolo[3,4-b-pyrazine and 1 gas-methyl-indolyl-4-methylpyrazine were used as starting materials to prepare zopiclone. The method has three problems; L flammable articles, safety in large-scale production is difficult to guarantee: 2 <lower yield, crude product yield 76%; 3> using a chromatography column during refining, which is not conducive to large-scale production.

1993年, 陈 昌等 [郑州大学学报(自然科学版), 1993, 25, ?3 ?6]报道: 以二氯甲 烷为溶剂, 6- (δ-Μ~2-««) -5-轻基- 7 -氧代 -5, 6-二氢 3比咯并 [3, 4 - fa] ¾嗪与 i -氣甲酰基 4 -甲基獰嗪盐酸盐为.康料制备佐匹克隆。 该方法主荽问题是反应不 彻底, 致使成品纯度偏低, 杂质含量偏高。  In 1993, Chen Chang et al. [Journal of Zhengzhou University (Natural Science Edition), 1993, 25, ?3 ?6] reported: using dichloromethane as solvent, 6-(δ-Μ~2-««) -5-light The benzyl- 7-oxo-5,6-dihydro 3-pyrolo[3,4- fa] 3⁄4-azine and the i-carbamoyl 4-methylpyridazine hydrochloride were used to prepare zopiclone. The main problem with this method is that the reaction is not thorough, resulting in low purity of the finished product and high impurity content.

1994年, 张雅芳等(中国药物化学杂志, 1994, 4 (1), 62-64)报遒; 以无水吡啶为 M' 6- (5-Μ~ ~ Φ : ) - 5 - - 7 -氧代 - 5, 6-二.氣 略并 [3, 4 - b] 嗉 -¾ 1 -氯甲载基 - -甲基哌睛盐酸盐为原料制备佐匹克隆。 该方法具有两个!'母题: 1-牧率 比较 粗品收率《 ; 2.析晶时采用将反应液倒入冰水中, 致使吡啶难以國收, 如果将 母液 (*锭与水的混合液〉 弃去, 不仅增加成本 同时也不利于环保。 耀点偏底, 达不 到欧洲药典的要求。 In 1994, Zhang Yafang et al. (Chinese Journal of Medicinal Chemistry, 1994, 4 (1), 62-64) reported 遒; anhydrous pyridine as M' 6- (5-Μ~ ~ Φ : ) - 5 - - 7 - oxygen Generation - 5, 6-II. Gaso[3,4-b] 嗉-3⁄4 1 -chloromethyl--methyl piperazine hydrochloride was used as a starting material to prepare zopiclone. The method has two!' motifs: 1-1 ratio of crude product yield; 2. The reaction solution is poured into ice water during crystallization, which makes the pyridine difficult to collect, if the mother liquor (* ingot mixed with water) Liquid> Abandoned, not only increases the cost but also is not conducive to environmental protection. The radiance is out of the bottom, and the requirements of the European Pharmacopoeia are not met.

S明内容 S content

本发明的目的在于克服现有技术的缺陷, 提供-种新的合成佐匹克隆的方法, 具有安 全可靠, 反应时间短 > 反应收率高, 产品质邋好的特点。  SUMMARY OF THE INVENTION The object of the present invention is to overcome the deficiencies of the prior art and to provide a novel method for synthesizing zopiclone which is characterized by safety and reliability, short reaction time > high reaction yield and good product quality.

本发明的技术方案如下;  The technical scheme of the present invention is as follows;

一种佐匹克隆的制备方法, e~ (5- ' '¾锭基) - 5 -径基 - 7-氧 - 5, 6 - 二 «咯并 ¾ 4 - b]fft嚷 与 1 -掇甲酰棊 - 4 -申基哌嗉益酸盐 为原料,在无水有机溶剂 中, 在碱性条件下, 以 4 -取代基吡啶为催化剂反应制得。 反应式如下;

Figure imgf000004_0001
A preparation method of zopiclone, e~(5- ''3⁄4 ingot) - 5 -diaperyl-7-oxy-5, 6 - 2 «desine 3⁄4 4 - b]fft嚷 and 1 - armor The hydrazide-4-propenylpiperazine acid salt is used as a raw material, and is obtained by reacting a 4-substituted pyridine as a catalyst under an alkaline condition in an anhydrous organic solvent. The reaction formula is as follows;
Figure imgf000004_0001

其中 R为叔胺基、 C! C8直链或支链烷烧、 C?〜C«芳烷烃、 C3〜C8环烷烃、 芳番 基  Wherein R is a tertiary amino group, a C! C8 linear or branched alkane, a C?~C« aryl alkane, a C3~C8 cycloalkane, an aromatic group.

其中, 无水有机溶剂是氣代嫁、 乙腈 四氯呋喃、 二氣六环、 丙酮、 乙酸乙酯、 ' -二甲基甲酰铵的一种或几种, 优选二氣甲烷。  Wherein, the anhydrous organic solvent is one or more of gas-married, acetonitrile, tetrachlorofuran, dioxane, acetone, ethyl acetate, '-dimethylformamide, preferably di-methane.

无水有机溶剂用凝是 6 (:5 氯 2-吡啶基) 5 ¾基-? -氧代 δ, 6··二 咯并 [3, 4- 3 吡壤的 10〜50重量倍; 优选的无水有机溶剂用量是 6- (5魏- 啶基〉 -·δ经基- 7-氧代 -δ, 6-二滅袼并〔3, 4 b] 嗪的 25〜35S量倍  The anhydrous organic solvent is 6 to 50 times by weight of 6 (:5 chloro-2-pyridyl) 5 3⁄4 yl-oxo-oxo, 6·di-[3,4- 3 pyridinium; The amount of anhydrous organic solvent is 6-(5-weityl)-·δ-trans-yl-7-oxo-δ, 6-dioxazide and [3, 4 b]azine in the amount of 25~35S

所述的碱性条件使用的是有机碱, 具体优选自甲胺、 二乙胺、 三乙胺、 二丙胺、 二异 丙胺、 环两胺、 环乙胺、 苯胺、 甲基笨胺、 N, -二甲基苯胺或吡啶之一或组合.。 有机碱 加量使 1.1为宜。  The alkaline condition is an organic base, and particularly preferably from methylamine, diethylamine, triethylamine, dipropylamine, diisopropylamine, cyclic diamine, cycloethylamine, aniline, methylamine, N, One or a combination of dimethylaniline or pyridine. The amount of organic base added is 1.1.

所述的催化剂 4 -取代基吡啶, 选自 4 -二甲胺基吡暖、 - 基吡啶、 4 - P 咯嫁基 ¾ 啶、 4 -哌啶基 *啶., - (4 甲基 -1 喊啶基) ¾啶或 4 -瑪琳基鍾之一,  The catalyst 4-substituted pyridine selected from the group consisting of 4-dimethylaminopyrazole, -ylpyridine, 4-P-glycolyl 3⁄4 pyridine, 4-piperidinyl*pyridine., - (4 methyl-1 Shouting pyridine) 3⁄4 pyridine or 4 - one of the Marinji clocks,

鶴的, 上述制备方法中加入吡啶作为助溶剂, 其用量是原料 6- (δ-氣- 2-義基) 5羟基 7 氧代- 5,6-二氨毗咯并〔3, 4- 嗪的 1〜2倍(重量)。  In the above preparation method, pyridine is added as a co-solvent, and the amount thereof is 6-(δ-gas-2-nyl) 5 hydroxy 7 oxo-5,6-diaminopyrrolo[3,4-azine 1 to 2 times (by weight).

优选的, 催化剂与原料 6- ( δ-氣- 2-吡啶基) - 5- 基- 7-氧代- 5, 6-二氯吡咯并 [ 4 b] 吡嗪的摩尔比是 (0.(H〜0,5) : 1。  Preferably, the molar ratio of the catalyst to the starting material 6-(δ-Gas-2-pyridyl)-5-yl-7-oxo-5,6-dichloropyrrolo[4b]pyrazine is (0. H~0,5): 1.

优选的,原料 6·- (5 «-2 P 啶基) 5-羟基 ? 氧代 -5, 6-·.二氣吡咯并 [3, 4 - b]吡嚓 与 i-¾甲酰基 -4-甲基喊嗪盐黢盐的摩尔比是 i: (1-1,7),  Preferably, the starting material 6·- (5 «-2 P pyridine) 5-hydroxy? The molar ratio of oxo-5,6-.dioxapyrrolo[3,4-b]pyridinium to i-3⁄4formyl-4-methylpyrazine salt is i: (1-1,7) ),

优选的, 反应温度为 iO 至溶剂体系得沸点。  Preferably, the reaction temperature is from iO to the boiling point of the solvent system.

优选的, 反应时簡是 i〜4,5小时。 更为优选的, 反应时间是 1.5〜3.5小时 优选的, 上述反应结束后, 逬行以下后处理- 向反应体系中加纯化水 分层, 水层弃去, 将二氮甲烧真空浓縮后, 加入乙酸乙酯升 &M 78V, 加话性炭鋭色, 过滤, 降温析晶, 过滤, 千燥, 得到类白色固体佐匹克隆 所 得产品的 ¾压液相 (HPLC) 图谱 (图 1所示) 与公知:佐匹克隆标准品的离压液相 (HPLC) 图谱一致》  Preferably, the reaction time is i~4, 5 hours. More preferably, the reaction time is preferably 1.5 to 3.5 hours. After the completion of the above reaction, the following post treatment is carried out - a water layer is added to the reaction system, the water layer is discarded, and the dinitrogen is vacuum concentrated. Add ethyl acetate liter & M 78V, addictive anthrax, filter, cool down and crystallize, filter, dry, and obtain a 3⁄4 pressure liquid phase (HPLC) spectrum of the product obtained from the white-like solid zopiclone (Figure 1 It is well known that the separation of the liquid phase (HPLC) of the zopiclone standard is consistent.

本发明的佐匹克隆的制备方法采用毒性比较小且不易燃爆的的有机溶剂, 反应彻底, 成品纯度高, 并取得了理想的收率。 本发明的佐匹克隆的 备方法的技术特点还在于: The preparation method of the zopiclone of the invention adopts an organic solvent which is relatively less toxic and is not flammable, and the reaction is thorough, the purity of the finished product is high, and an ideal yield is obtained. The technical feature of the preparation method of zopiclone of the present invention is also:

1. 催化剂的选择, 本发明经大量的实验以外地发现 4 -取代基吡啶可以加快佐匹克隆 制备的反应速度, 并能减少副反应, 从而提离产品的收率和潢量。 1. Selection of Catalysts The present invention has found, in addition to a large number of experiments, that 4-substituted pyridine can accelerate the reaction rate of zopiclone preparation and reduce side reactions, thereby extracting product yield and yield.

2. 本发明催化剂 4-取代基 «啶与反应物 S-(5 氯 2 吡啶基 ) 5-羟基-? -氧代 6-- 二氣吡略并 [3,4-b]吡嗪的摩尔比特别优选 0.0i〜0.5: Ϊ, 经实验验证我 fl发现谈摩尔比 低于 0.01: 1就不能明显地提离反应速度,若离于 0.5: Ϊ与糜尔比在 ί).01: 1与 5: 1之 间对反应速度的提高没有明显的差别, 徒然增加了催化 的投斜量, 从而增加了生产成本2. The catalyst 4-reactive radical "pyridine" of the invention is reacted with the reactant S-(5 chloro-2-pyridyl) 5-hydroxy-?-oxo 6-dioxapyrido[3,4-b]pyrazine The ratio is particularly preferably 0.0i~0.5: Ϊ, I have found through experiments that I can't clearly lift the reaction rate when the molar ratio is less than 0.01:1, if it is from 0.5: Ϊ and 糜尔比在ί).01: 1 With 5: 1 There is no significant difference in the improvement of the reaction rate, which increases the amount of catalytic tilt, which increases the production cost.

3. 本发明反应温度优选是- 10Ό至溶剂体系得沸点, 如果低于 ΪΟΌ , 反应缓慢会发生 副反应, 同时还得延长反应时阀,额外增加劳动成本。3. The reaction temperature of the present invention is preferably -10 Torr to the boiling point of the solvent system. If it is lower than ΪΟΌ, the reaction will be delayed, and the reaction will be prolonged, and the labor cost will be increased.

. 本发明反应时简优选是 ϊ ~4小时 经实验验证我们发现反应时间低于 Ϊ小时会使 反应不彻底; 反应时阆高于 4. 5小时不仅不会提髙产品的收率, 反而使产品的颜色加深。  The reaction time of the present invention is preferably ϊ4 hours. It has been verified by experiments that we found that the reaction time is less than Ϊhour, which makes the reaction incomplete. The reaction time is higher than 4.5 hours, which not only does not increase the yield of the product, but instead The color of the product is deepened.

本发明的佐匹克隆的制备方法除具有以上特点外, 还具有安全可靠, 反应时间短, 反 应收率高, 产品质量好的特点。 In addition to the above characteristics, the preparation method of the zopiclone of the invention has the characteristics of safety and reliability, short reaction time, high reaction yield and good product quality.

m  m

图 1是本发明所得产品的高'压液相 (H :) 图谱, 横坐标时间, 单位分钟。  BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a high 'pressure liquid (H:) spectrum of the product of the present invention, abscissa time, in minutes.

具体实施方式 detailed description

下面结合实施琬对本发明做进一歩说明, 但不限于此。  The present invention will be further described below in conjunction with the implementation, but is not limited thereto.

实施树 I t  Implementation tree I t

向 500 反应瓶中依次投入 250g二氯甲烷, 10. Og 6 - ( 5 -鉞 - 2 -- ¾啶基) - 5 - 羟基 -? -氧代 - S, 6 二滅略并〔3, 4 - b]吡嗪, 10, Og 1 -氣甲酰基 - 4 -甲基喊嗪盐酸 盐, I 1M 吡啶, 乙胺和 i. Og 4 -二甲胺基吡啶,升温至回流, 保温反应 1. 5小时; 然后 加入 iOOai纯化水, 分层, 水层弃去 将二氯甲烷真 S浓缩后, 加入 150ral乙酸乙 酯升温至? 8t:, 加入 g活性炭, 搅拌 30分钟, 过滤, 降温析晶, 过滤, 千燦, 得到佐匹 克隆类白色固体 13, 7¾收率 92. 9%, 含量 98, 5% (HPLC )。  Into a 500 reaction flask, 250 g of dichloromethane, 10. Og 6 - ( 5 -钺 - 2 - 3⁄4-pyridyl) - 5 -hydroxy-? -oxo-S,6 di- succinyl [3,4-b]pyrazine, 10, Og 1 -carbamoyl-4-methylpyrazine hydrochloride, I 1M pyridine, ethylamine and i. 4-dimethylaminopyridine, the temperature was raised to reflux, and the reaction was kept for 1.5 hours. Then, iOOai purified water was added, the layers were separated, and the aqueous layer was discarded. The methylene chloride was concentrated. 8t:, add g activated carbon, stir for 30 minutes, filter, cool down and crystallize, filter, and obtain a white solid of zopicl, 13. 73⁄4 yield 92.9%, content 98, 5% (HPLC).

实施例 2:  Example 2:

向 5Wnd反慮瓶中依次投入 35i)g二氣甲烷, 10. ¾ 6- (5 氯 2-吡啶基〉 5经基?- 氧代 δ, 6 二氯吡咯并 [3, 4 - 1x1吡嗪, iO. Og 1-氣甲酰基- 4 甲基哌嗪盆酸盐, Ilmi 吡啶, 15 二 胺和 2. Og 4 二甲胺基毗锭,升温至阁流, 保温反应 1小时;. 然后, 加入 iOOmi 纯化水, 分层, 水层弃去,将二氣甲烷真空浓缩后,加入 ΐ50¾ι乙酸乙酯升温至? c, 加入 lg活性炭,搅 分钟》过滤, 降温析晶,过滤,干燥,得到佐匹克 it类白色固体 14.00g, 收率 94. 59%, 含量^ . 3% ( HPLC)。  Into the 5Wnd counter-injection bottle, 35i) g of di-methane, 10. 3⁄4 6-(5-chloro-2-pyridyl) 5-based oxo-oxo, 6-dichloropyrrolo[3, 4 -1x1 pyrazine , iO. Og 1-carboyl- 4 -methylpiperazine bath salt, Ilmi pyridine, 15 diamine and 2. Og 4 dimethylamine bisphenol, heated to the chamber flow, and the reaction was kept for 1 hour; Add iOOmi purified water, layer, discard the water layer, dilute the methane methane in vacuo, add ΐ 503⁄4ι ethyl acetate to raise the temperature to c, add lg activated carbon, stir for a while, filter, cool and crystallize, filter, dry, get the Pico it white solid 14.00 g, yield 94. 59%, content ^. 3% (HPLC).

实施例 3;  Example 3;

向 5編反应瓶中依次投入 25¾Ν, Ν -二甲基甲酰胺, 1.0. Og 6 (5氣 2吡啶基) 5经基- 7 氧代 5> 6-二¾吡咯并 [3, 4 - bmm> 10. Og 1 氣甲麟基 ·4-甲基哌嗪盐酸盐, 漏 ¾啶, 編二异丙胺和 1. Og 4 -二甲胺基吡啶,在 25'C保温反应 3. 0小时; 然后, 加入 10¾1纯化水, 分层, 水层弃去, 将 N, N -二 φ基甲酰胺真空浓缩后, 加入 乙 酸乙醱升温至 78'C , 加入 lg活性炭, 搅拌 30分钟, 过滤, 降温析晶, 过滤, 干燥, 得到 佐匹克隆类白色固体 13. 6g,牧率 91.89%, 含量 98. 0¾ CHPLC),  Into a 5-bed reaction flask, 253⁄4 Ν, Ν-dimethylformamide, 1.0. Og 6 (5 gas 2 pyridyl) 5 thiol 7 oxo 5> 6-di 3⁄4 pyrrole [3, 4 - bmm O. 1 Og 1 甲甲基基·4-methylpiperazine hydrochloride, 3⁄4 pyridine, diisopropylamine and 1. Og 4 -dimethylaminopyridine, incubated at 25 ° C 3. 0 hours Then, 103⁄41 purified water was added, the layers were separated, and the aqueous layer was discarded. After concentrating the N,N-di-ytylformamide in vacuo, the mixture was heated to 78 ° C by adding acetonitrile, stirred for 30 minutes, and filtered. The temperature is crystallization, filtration, and drying, to obtain a white solid of zopiclone 13.6 g, grazing rate 91.89%, content 98. 03⁄4 CHPLC),

实施例 4:  Example 4:

向 500ml反应瓶中依次投入 350gN, ^二甲基甲酰胺, 10. 0g 6- (5-氯-' 2-吡啶基) -5 羟基- 7 -氧代 5, δ-二氯吡咯并 [3, 4 - b]吡嗪, 10. 0g i 氯甲轔基 甲基鴨嗪盐酸盐, 2(½ϊ 吡啶 {¾1三乙胺和 i. Og 4-哌啶基吡啶,升温至回流, 保滠反应 i, 5小时; 然后, 加入 ICKimi纯化水, 分层, 水层弃去 * 将 N, N -二甲基甲酰胺真空浓縮后, 加入 150 乙 酸乙酯升温至 78Ό, 加入 lg活性炭, 携拌 30分钟, 过滤, 降温析晶 过滤, 千燥, 得到 佐匹克隆类白色固体 3,.32g,收率 90,0¾, 含量 99,« <HFlC)e Into a 500 ml reaction flask, 350 g of N, ^ dimethylformamide, 10. 0 g of 6-(5-chloro-' 2-pyridyl)-5 hydroxy-7-oxo 5, δ-dichloropyrrolo[3] were sequentially introduced. , 4 - b] pyrazine, 10. 0g i chloromethylmethylmethyl sulfazine hydrochloride, 2 (1⁄2ϊ pyridine {3⁄41 triethylamine and i. Og 4-piperidylpyridine, warmed to reflux, protected Reaction i, 5 hours; then, add ICKimi purified water, layer, the water layer is discarded * Concentrate N, N-dimethylformamide in vacuo, add 150 B Ethyl acetate was heated to 78 Ό, lg activated carbon was added, mixed for 30 minutes, filtered, cooled and crystallized and filtered, dried to obtain 3,.32 g of zopiclone white solid, yield 90,03⁄4, content 99, « <HFlC ) e

Figure imgf000006_0001
Figure imgf000006_0001

Claims

i、 一种佐匹克隆的制备方法, 以 6 - (5 - - 2 -鳴啶基) ~ 5 - ¾¾ - 7 -氧代 - 5, 6 -二氯吡咯并 [¾ 4 - b] H» 与 1 -氣平鼠基 - 4 甲基喊嚷盐酸盐 为原料,在无水有机溶 剂中, 在碱性条件下, 以 4 -取代基 啶为催化剂反应制得; 反应式如下 ί i, a preparation method of zopiclone, 6 - (5 - - 2 - oxaridinyl) ~ 5 - 3⁄43⁄4 - 7 - oxo - 5, 6 - dichloropyrrolo[3⁄4 4 - b] H» It is prepared by reacting 1 - gas flat mouse - 4 methyl sulfonate hydrochloride in an anhydrous organic solvent under alkaline conditions with 4 -substituted pyridine as a catalyst;
Figure imgf000007_0001
Figure imgf000007_0001
其中 R为叔胺基, C〜CS直链或支链燒烃、 C7~C!5芳烷 、 C3〜C8环烷烃、 芳香 利  Wherein R is a tertiary amine group, a C~CS linear or branched hydrocarbon, a C7~C!5 aralkyl, a C3~C8 cycloalkane, a fragrance 其中, 无水有机溶剂是氣代綜、 乙腈、 四氯呋喃、 二氧六环、 簡、 乙 K乙酯、 , N -二甲基甲酰胺的一种或几种, 无水有机溶姻用要量是 6 ( 5 氣 2-吡啶基) 5羟基- 7 -氧 代 6-二氢吡 并〔3, 4 b] «嗦的 10〜50重量倍; 优选 25〜35重量倍。  The anhydrous organic solvent is one or more of gas, acetonitrile, tetrachlorofuran, dioxane, succinyl, ethyl ethyl ethoxide, and N-dimethylformamide, and is used for anhydrous organic dissolution. The amount is 6 (5 gas 2-pyridyl) 5 hydroxy-7-oxo 6-dihydropyridin [3, 4 b] « 10 to 50 weight times of hydrazine; preferably 25 to 35 weight times.
2、 如权利要求 i所述的佐匹克隆的制备方法, 其特征在于无水有机溶剂是二氯甲焼 The method for producing zopiclone according to claim 1, wherein the anhydrous organic solvent is dichloromethane. 3、如权莉要求 i街述的佐 2£克隆的制备方法,其特征在于所 ¾¾碱性条件使用的甲胺、 二乙胺、 三乙胺, 二丙胺、 二异丙胺、 环丙胺、 环乙胺、 苯胺、 甲基苯胺、 二甲基 苯胺或 啶之一或组合, 有机碱加量使 pH-8 U为宜。 3. A method for preparing a clone of Zuo 2, such as Quan Li, which is characterized in that methylamine, diethylamine, triethylamine, dipropylamine, diisopropylamine, cyclopropylamine, and a ring are used in an alkaline condition. One or a combination of ethylamine, aniline, methylaniline, dimethylaniline or pyridine, the amount of the organic base is preferably pH-8 U. 4、 如权利要求 1所述的佐匹克隆的制备方法 > 其特征在于所逑的催化剂 4 -取代基吡 啶逸自 4 二甲胺基吡啶、 4 -苄基 ¾啶、 4 -;吡咯烷基吡锭、 4 -哌啶基 !«啶, - (4 甲基 i 哌瘦基) β 锭或 4 -吗啉基吡啶之一》  4. Process for the preparation of zopiclone according to claim 1 characterized in that the catalyst 4 -substituted pyridine is derived from 4 dimethylaminopyridine, 4-benzyl 3⁄4 pyridine, 4 - pyrrolidinyl group Pyridine, 4-piperidinyl! «Acridine, - (4 methyl i piperidyl) β ingot or one of 4-morpholinylpyridine 5, 如权利要求 Ϊ所述的佐匹克隆的制备方法, 其特征在于加入毗啶作为助溶剂, 其用 量是原料 6- ( 5氣- ·2-吡啶基) 5羟基 Τ氧代 5, 6 二氳吡咯并!:3, 4 b〗Sft嗪的 1〜2重量 倍 ·  The method for preparing zopiclone according to claim 1, wherein a pyridin is added as a co-solvent in an amount of 6-(5 gas-·2-pyridyl) 5 hydroxy oxime 5, 6 Dioxapyrrole! :3, 4 b〗 Sftazine 1~2 weight times · 6、 如权利要求 1所述的佐匹克隆的制备方法, 其特征在于催化剂与瘰料 (S~ ~2~ 吡啶基) -5-羟基- 7-氧代- δ, δ-二氯吡咯并 [3, 4- b]吡嗪.的摩尔比是 ¾ 01〜 5) : ί。  The method for preparing zopiclone according to claim 1, characterized in that the catalyst and the mash (S~~2~pyridyl)-5-hydroxy-7-oxo-δ, δ-dichloropyrrole The molar ratio of [3, 4-b]pyrazine is 3⁄4 01~ 5) : ί. ?、 如:权利要求 1所逑的佐匹克隆的制备方法, 其特征在于攝料 6- ( 5-氯- 2- ft啶棊) - S羟基 ? 氧代 5, 6 二¾吡咯并 [3, 4 ~ b〕吡嗪 与 1 氯甲酰基 4 甲基哌嗪盐酸盐的摩尔 比是 1: <1〜L 7)。  ? The preparation method of zopiclone according to claim 1, characterized in that 6-( 5-chloro-2- ft pyridine)-S hydroxy oxo 5, 6 bis 3⁄4 pyrrole [3, The molar ratio of 4 to b]pyrazine to 1 chloroformyl-4-methylpiperazine hydrochloride is 1: <1 to L 7). 8、 如权利要求 1所述的佐匹兗隆的制备方法, 其特征在于反应温度为 10Ό至溶剂体 系得沸点。  The method for producing zopiclone according to claim 1, wherein the reaction temperature is from 10 Torr to the boiling point of the solvent system. 9、 如权利要求 I所述的佐匹克隆的制备方法, 其特征在于反应时间是 I 4. S小时。 Ϊ0、 如权利要求〗所述的佐 2S克隆的制备方法, 其特征在于反应结束后, 进行以下后 处理; 向反应体系中加纯化水 分展, 水還弃去 将二氣甲烷真空浓缩后, 加入^酸乙醋 升温至?8υ , 加活性炭鋭色, 过滤,, 降温析難, 过滤, 千燥, 得到类白色固体佐匹克隆。  9. A method of producing zopiclone according to claim 1, wherein the reaction time is I 4. S hours. Ϊ0. The preparation method of the 2S clone according to the claim, characterized in that after the reaction is finished, the following post-treatment is carried out; the purified water is added to the reaction system, and the water is discarded, and the two-gas methane is concentrated in vacuo, and then added. ^Is the acid vinegar warmed up to? 8υ, add activated carbon ochre, filter, and reduce temperature, filter, dry, get white-like solid zopiclone.
PCT/CN2008/072007 2007-12-19 2008-08-15 A method for preparing zopiclone Ceased WO2009079939A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200710115636.0 2007-12-19
CNB2007101156360A CN100467471C (en) 2007-12-19 2007-12-19 Preparation method of zopiclone

Publications (1)

Publication Number Publication Date
WO2009079939A1 true WO2009079939A1 (en) 2009-07-02

Family

ID=39546266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2008/072007 Ceased WO2009079939A1 (en) 2007-12-19 2008-08-15 A method for preparing zopiclone

Country Status (2)

Country Link
CN (1) CN100467471C (en)
WO (1) WO2009079939A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100467471C (en) * 2007-12-19 2009-03-11 齐鲁天和惠世制药有限公司 Preparation method of zopiclone
CN106220630B (en) * 2016-07-23 2019-12-10 迪嘉药业集团有限公司 Preparation method of N-substituted pyrrolo [3,4-B ] pyrazine-5, 7(6H) -diketone
CN111007184B (en) * 2019-12-30 2023-05-16 天津天士力圣特制药有限公司 Method for detecting content of 4-methylpiperazine-1-formyl chloride hydrochloride
CN112094275A (en) * 2020-09-16 2020-12-18 迪嘉药业集团有限公司 Preparation method of (Eszopiclone) photodegradation impurities
CN114763342A (en) * 2021-01-09 2022-07-19 江苏天士力帝益药业有限公司 Synthesis method of high-purity 4-methylpiperazine-1-formic ether

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862149A (en) * 1972-01-07 1975-01-21 Rhone Poulenc Sa Pyrrolo (3,4-b) pyrazine derivatives
US7189715B2 (en) * 2002-10-24 2007-03-13 Sepracor Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
WO2008002629A1 (en) * 2006-06-26 2008-01-03 Teva Pharmaceutical Industries Ltd. Process for the preparation of zopiclone
CN101195624A (en) * 2007-12-19 2008-06-11 齐鲁天和惠世制药有限公司 Method for preparing zopiclone

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862149A (en) * 1972-01-07 1975-01-21 Rhone Poulenc Sa Pyrrolo (3,4-b) pyrazine derivatives
US7189715B2 (en) * 2002-10-24 2007-03-13 Sepracor Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
WO2008002629A1 (en) * 2006-06-26 2008-01-03 Teva Pharmaceutical Industries Ltd. Process for the preparation of zopiclone
CN101195624A (en) * 2007-12-19 2008-06-11 齐鲁天和惠世制药有限公司 Method for preparing zopiclone

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RAMIAH MURUGAN ET AL.: "Applications of dialkylaminopyridine (DMAP) catalysts in organic synthesis.", ALDRICHMICAACTA, vol. 36, no. 1, 2003, pages 21 - 27 *
ZHANG YAFANG ET AL.: "Synthesis of the new sedative hypnotic zopiclone.", CHINESE JOURNAL OF MEDICINAL CHEMISTRY, vol. 4, no. 1, March 1994 (1994-03-01), pages 62 - 64 *

Also Published As

Publication number Publication date
CN101195624A (en) 2008-06-11
CN100467471C (en) 2009-03-11

Similar Documents

Publication Publication Date Title
WO2009079939A1 (en) A method for preparing zopiclone
TW200951102A (en) Resolving of 4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane
CN104496989A (en) Industrial preparation process of linagliptin
CN102659494A (en) Method for asymmetric synthesis of 3,3-disubstituted-2-oxindole compound
CN103509025A (en) Preparation method of epinastine hydrochloride and intermediate thereof
TW200817376A (en) Dual molecules containing a peroxide derivative, synthesis thereof and therapeutic applications thereof
CN102126976A (en) Intermediates of Sitagliptin and preparation method thereof
CN106554354A (en) The intermediate of Li Gelieting or its analog and Li Gelieting or the preparation method of its analog
CN110734393B (en) Preparation method of N-benzyl-3-oxopiperidine-4-carboxylic acid ethyl ester hydrochloride
CN107365301B (en) Synthesis method of crizotinib and preparation method of intermediate thereof
CN104151291A (en) Preparation method for benzoic acid alogliptin polycrystalline type crystal
CN114075201B (en) Preparation method of sitagliptin impurity
CN104418855A (en) Improved method for preparing paliperidone and intermediates of paliperidone
KR101001646B1 (en) Method for preparing (R)-(+)-lansoprazole and intermediates used therein
CN102363599A (en) Chiral resolution method of sitagliptin intermediate
WO2021208711A1 (en) Application of tylophora alkaloid or salt thereof in resisting coronavirus
CN112341433A (en) A kind of preparation method of loratadine
WO2021259051A1 (en) Method for improving synthesis process of hypidone free base
CN105111209B (en) Aza-indoline compound and method for preparing same
CN105712920B (en) A kind of preparation method of vildagliptin
CN117126078B (en) A class of compounds and their use in the treatment of hDHODH-mediated diseases
CN108409649A (en) A kind of synthetic method of the bromo- 7- Trifluoromethylquinocarboxylics of 5-
CN103739541A (en) Preparation method of 5,6-dihydro-3-(4-morpholinyl)-1-[4-(2-oxy-1-piperidyl) phenyl]-2(1H)-pyridone
CN102264735A (en) One-step process for preparing paliperidone and its oxalate salt
CN113896730B (en) Preparation method of tofacitinib citrate and intermediate thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08783998

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08783998

Country of ref document: EP

Kind code of ref document: A1